Antiviral Drug Discovery and Mechanisms of Resistance – ZRG1 AIDC (82)
The Antiviral Drug Discovery and Mechanisms of Resistance (AIDC (82)) study section reviews applications in the area of antiviral drug discovery that would otherwise be reviewed by the Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR) study section.
Review Dates
Topics
- Anti-infective drug discovery: drug target identification, characterization and validation; novel screening methods and assay development; molecular and medicinal chemical characterization of inhibitors; structure-guided drug design; preclinical studies using animal models
- Antiviral resistance: mechanisms and regulation of resistance; emergence, dissemination, and maintenance of resistance; strategies for the prevention of resistance; molecular characterization of resistance
Shared Interests and Overlaps:
There are shared interests with Synthetic and Biological Chemistry A Study Section (SBCA) and Synthetic and Biological Chemistry B Study Section (SBCB) in the area of anti-infective drug development. Applications focused on the syntheses of small molecules or natural products with limited biological assessments may be reviewed in SBCA or SBCB, whereas applications involving some synthesis but more focused on the preclinical biological characterization of leads may be reviewed here.
There are shared interests with High-Throughput Screening Special Emphasis Panel (BST (55)) in the area of anti-infective drug discovery and development. Applications that focus on developing novel high-throughput screens for small molecule hits and immunotherapeutics may be reviewed in BST (55), whereas applications that focus on identifying anti-infective targets, molecular mechanisms of action, and the development of lead compounds for anti-infective therapeutics may be reviewed here.
There are shared interests with Vaccines Against Microbial Diseases (VMD), Virology A (VIRA) & Virology B (VIRB) in the area of antiviral strategies. Applications that focus on the pathogenesis of viruses using known drugs or molecular probes may be reviewed in VIRA or VIRB. Applications that focus on immunotherapies that use antibodies and vaccines may be reviewed in VIRB or VMD. Applications that focus on antiviral drugs (for example, small molecule compounds, peptides, nucleic acids) or mechanisms of antiviral drug resistance may be reviewed here.
